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Abstract Functional evidence suggests that the stimula-
tion of peripheral and central opioid receptors (ORs) is able
to modulate heart function. Moreover, selective stimulation
of either cardiac or central ORs evokes preconditioning
and, therefore, protects the heart against ischemic injury.
However, anatomic evidence for OR subtypes in the human
heart is scarce. Human heart tissue obtained during autopsy
after sudden death was examined immunohistochemically
for mu- (MOR), kappa- (KOR), and delta- (DOR) OR
subtypes. MOR and DOR immunoreactivity was found
mainly in myocardial cells, as well as on sparse individual
nerve fibers. KOR immunoreactivity was identified pre-
dominantly in myocardial cells and on intrinsic cardiac
adrenergic (ICA) cell-like structures. Double immunoflu-
orescence confocal microscopy revealed that DOR colo-
calized with the neuronal marker PGP9.5, as well as with
the sensory neuron marker calcitonin gene-related peptide
(CGRP). CGRP-immunoreactive (IR) fibers were detected
either in nerve bundles or as sparse individual fibers con-
taining varicose-like structures. Our findings offer the first
hint of an anatomic basis for the existence of OR subtypes in
the human heart by demonstrating their presence in CGRP-
IR sensory nerve fibers, small cells with an eccentric nucleus
resembling ICA cells, and myocardial cells. Taken together,
this suggests the role of opioids in both the neural trans-
mission and regulation of myocardial cell function.
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Introduction
There is a growing body of data supporting a peripheral
role for opioids in the regulation of organ function, such
as the gut [1], lungs [2, 3], and heart [4]. Experimental
studies have shown that stimulation of both peripheral
(cardiac) and central opioid receptors (ORs) is able to
modulate heart function and evoke cardioprotection
against ischemia [5–7]. The efficacy of opioids in
inducing preconditioning and postconditioning not only in
intact hearts in vivo [8] but also in isolated cardiomyo-
cytes in vitro [9, 10], their inotropic effects [11–13], and
their impact on growth factor expression [14, 15] in cell
culture indicate the presence of ORs on cardiomyocytes
and not only on neural elements.
The function of the heart is controlled by the autonomic
nervous system. It is widely accepted that the heart has an
intrinsic cardiac nervous system, or ‘‘heart brain,’’ con-
sisting of a complex network of intrinsic cardiac ganglia,
sensory afferents, local circuits, and pre- and postgangli-
onic parasympathetic and postganglionic sympathetic
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efferents. We have consistently shown in rats that mu-OR
(MOR), delta-OR (DOR), and kappa-OR (KOR) are
expressed as mRNA and translated into specific receptor
proteins on different components of the intrinsic cardiac
nervous system [16, 17].
To date, anatomic evidence for the different OR subtypes
in the human heart has been scarce. Most investigators have
confirmed the presence of DOR mRNA and protein, but there
is still conflicting evidence for MOR and KOR [18–20].
Moreover, immunohistochemical studies of their anatomic
distribution are lacking. Therefore, we examined the pre-
sence of MOR, DOR, and KOR throughout human heart
tissue sampled from victims of sudden death.
Materials and methods
Patients and the preparation of human heart tissue
The study protocol adhered to the International Guidelines
of the Declaration of Helsinki 2004 (World Medical
Association: http://www.wma.net) and was approved by
the Ethics Committee of the Nicolaus Copernicus Univer-
sity in Torun, Poland. Human heart tissue samples were
obtained from two subjects (females, 37 and 42 years of
age) up to 48 h after sudden death during postmortem
examination in the Forensic Medicine Department, By-
dgoszcz. The younger female died as a result of suicide.
The older female died unexpectedly and during autopsy,
atherosclerotic changes in the coronaries and focuses of
myolysis and nuclear fragmentation were identified, which
gave the suspicion of a very recent myocardial infarction.
Both were nonsmokers. Samples (at least 1 cm3 each) were
taken from five different regions, two from each location:
the right atrium between the caval veins, the free wall of
the right ventricle, the intraventricular septum, the anterior
wall of the left ventricle including the left anterior
descending coronary artery, and the inferior wall of the left
ventricle. Tissue samples were fixed in 4 % (w/v) para-
formaldehyde in 0.16 M phosphate buffer solution (pH 7.4)
for 5 h and then cryoprotected overnight at 4 C in phos-
phate-buffered saline (PBS) containing 10 % sucrose [21].
The tissues were embedded in Tissue-Tek compound
(OCT; Miles, Elkhart, IN, USA). Then 50-lm thick sec-
tions were processed in a cryostat and collected in PBS
(floating sections).
Single immunostaining for light microscopy
Floating tissue sections were processed for MOR, DOR,
or KOR immunohistochemistry with a Vectastain avidin–
biotin–peroxidase complex (ABC) kit (Vector
Laboratories, Burlingame, CA, USA) as described pre-
viously [21, 22]. All incubations were carried out at
room temperature, and PBS was used for washing (three
times for 10 min) after each step. Sections were incu-
bated for 45 min in PBS with 0.6 % H2O2 and 50 %
methanol to block endogenous peroxidase, and for 60
min in PBS containing 0.3 % Triton X-100, 1 % bovine
serum albumin, and 10 % goat serum (Vector Labora-
tories) (blocking solution) to prevent nonspecific binding.
The sections were then incubated overnight with poly-
clonal rabbit antibodies against MOR (a gift from S.
Schulz and V. Ho¨llt, Magdeburg, Germany), DOR (a gift
from R. Elde, Minneapolis, MN, USA), or KOR (a gift
from S.J. Watson, MI, USA), and thereafter for 90 min
with a goat antirabbit biotinylated secondary antibody
(Vector Laboratories) and for another 90 min with ABC.
Finally, specific immunostaining was detected with 30,30-
disaminobenzidine tetrahydrochloride (Sigma, Taufkir-
chen, Germany). Rabbit polyclonal anti-MOR, anti-DOR,
and anti-KOR have been thoroughly characterized pre-
viously [16, 17, 23]. Their immunoreactivity is lost upon
gene deletion of the respective receptors in transgenic
animals [24] or on Western blot following preincubation
with the respective antigen peptide [16, 17, 23]. In
addition, there is no cross-reactivity between these anti-
sera, since they do not stain the other receptors following
their respective transfection into cell lines [25–27].
Double immunofluorescence staining
Double immunofluorescence staining was performed as
described previously [22]. In brief, floating tissue sections
were incubated for 60 min in blocking solution. The sec-
tions were then incubated overnight with the following
antibodies: (1) rabbit polyclonal anti-DOR (dilution:
1:1000) in combination with chicken polyclonal protein
gene product 9.5 (PGP9.5) antibody (dilution: 1:500;
EnCor Biotechnology, Gainesville, FL, USA) or guinea
pig polyclonal calcitonin gene-related peptide (CGRP)
antibody (dilution: 1:500; Peninsula Laboratories, San
Carlos, CA, USA). After incubation with primary anti-
bodies, the tissue sections were washed with PBS and then
incubated with the appropriate secondary antibodies. After
incubation with primary antibodies, the tissue sections
were washed with PBS and then incubated with Texas Red
conjugated goat antirabbit antibody (Vector Laboratories)
in combination with Alexa Fluor 488 goat anti-guinea pig
or antichicken antibody (Invitrogen, Karlsruhe, Germany).
Thereafter, sections were washed with PBS, and the nuclei
stained bright blue with 40-6-diamidino-2-phenylindole
(0.1 lg/ml in PBS) (Sigma). Finally, the tissues were
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washed in PBS, mounted in Vectashield (Vector Labora-
tories), and imaged on a confocal laser scanning micro-
scope, Zeiss LSM 510 (Carl Zeiss, Go¨ttingen, Germany).
To demonstrate specificity of staining, the following con-
trols were included as described thoroughly in detail
elsewhere [16, 17, 28–30]: (1) preabsorption of diluted
antibody against MOR, DOR, or KOR with 5 lg/ml of
synthetic peptide antigen for MOR (Gramsch Laboratories,
Schwabhausen, Germany), DOR (Neuromics, Minneapo-
lis, MN, USA), or KOR (S.J. Watson), respectively, for 24
h at 4 C; and (2) omission of either the primary or sec-
ondary antibodies.
Fig. 1 Immunohistochemical localization of calcitonin gene-related
peptide (CGRP) in the right and left ventricles of human heart tissue.
a CGRP immunoreactivity expressed in nerve processes coursing in
nerve bundles. b–d CGRP immunoreactivity localized to some nerve
processes arborizing throughout the right ventricle tissue, containing
localized bead-like enlargements of the axoplasm (arrowheads) along
their lengths. c, f CGRP immunohistochemical localization in the left
ventricle. Note that CGRP is expressed in sparse, fine, and varicose
nerve fibers. Bar 20 lm
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Results
Identification of CGRP-immunoreactive sensory nerve
fibers in human myocardial tissue
In the right ventricle of the human heart, the majority of
CGRP immunoreactivity consisted of nerve processes
coursing in nerve bundles together with nonstained nerve
processes (Fig. 1a–d). In addition, CGRP-stained
individual nerve fibers arborizing throughout the right
ventricle myocardium contained localized, bead-like
enlargements of the axoplasm along their course. Histo-
logically, these enlargements resembled varicosities. In the
free wall of the left ventricle, sensory nerve fibers were
usually sparse, fine, and varicose, and exhibited CGRP
immunoreactivity (Fig. 1e, f). An abundant supply of
CGRP-immunoreactive (IR) nerve bundles and varicose
nerve fibers was distributed throughout the intraventricular
Fig. 2 Immunohistochemical localization of CGRP immunoreactiv-
ity in the intraventricular septum (a–e) and right atrium (f) of human
myocardial tissue. a–c An abundant supply of CGRP-immunoreactive
nerve trunks (b, c), nerve fascicles (e), and varicose nerve fibers (a,
d). f CGRP in the right atrium. Note that CGRP is expressed in sparse,
fine, and varicose nerve fibers. Bar 20 lm
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septum (Fig. 2a–e). Single CGRP-IR nerve fibers in the
right atrium were usually sparse, fine, and varicose (Fig.
2f).
Identification of MOR, DOR, and KOR
immunoreactivity in human myocardial tissue
Light microscopy pictures of human myocardium immu-
nostained with a specific antibody against MOR identified
a high degree of MOR immunoreactivity inside myocardial
cells in the inferior wall of the left ventricle (Fig. 3a, b). In
addition, MOR immunoreactivity was demonstrated in
sparse fine nerve fibers taking their course through human
myocardium in the intraventricular septum and inferior
wall of the left ventricle (Fig. 3c).
Delta opioid receptors (DOR) immunoreactivity was
located in the free wall of the right ventricle and in the
intraventricular septum, predominantly on longitudinal
structures corresponding to nerves. Some of the DOR-IR
thin nerve fibers were in close proximity to small artery
walls (Fig. 3e), whereas others lay between cardiomyocytes
(Fig. 3f). DOR immunoreactivity was also identified inside
myocardial cells of the right ventricle (Fig. 3g). KOR
immunoreactivity was demonstrated in the right ventricle
and intraventricular septum of human myocardium in
sparse fine nerve fibers between cardiomyocytes (Fig. 4a),
Fig. 3 Immunohistochemical localization of mu opioid receptor
(MOR) (a–d) or delta opioid receptor (DOR) (e–g) in human
myocardial tissue. a, b MOR expressed in myocardial cells of the
human heart. c MOR expressed in sparse solitary nerve processes in
cardiac tissue. d Preabsorption of antibody against MOR with 5 lg/ml
of synthetic peptide antigen for MOR revealed no significant
immunoreactivity. e–g DOR-immunoreactive nerve fibers in human
myocardial tissue was usually sparse, fine, and varicose. g DOR was
expressed in cardiomyocytes of the human heart. Bar 20 lm
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inside myocardial cells (Fig. 4b–d), and occasionally on
long fusiform cells with an eccentrically located large
nucleus resembling intrinsic cardiac adrenergic (ICA) cell-
like structures (Fig. 4d, e). Preabsorption of primary anti-
bodies against MOR, DOR, or KOR with 5 lg/ml of the
respective synthetic peptide antigen for MOR, DOR, or
KOR as well as the omission of the primary antibody
revealed no significant immunoreactivity (Fig. 3d).
Coexpression of DOR in CGRP-IR and PGP9.5-IR
neurons of human myocardial tissue
Double immunofluorescence confocal microscopy demon-
strated that human myocardium was densely innervated by
the general neuronal marker PGP9.5-IR (fluorescein iso-
thiocyanate (FITC) green) axons (Fig. 5b, e), some of
which also displayed DOR (Texas Red) immunoreactivity
(Fig. 5a, c, d, f). Some nerve fibers were immunolabeled
for PGP9.5 alone (Fig. 5c, f). In addition, double immu-
nofluorescence confocal microscopy of human heart tissue
demonstrated afferent nerve fibers coexpressing the sen-
sory neuronal marker CGRP (FITC green) (Fig. 5h, k),
which were colocalized with DOR immunoreactivity (Fig.
5g, i, j, l).
Discussion
The findings of this study demonstrate for the first time the
immunohistochemical localization of all three ORs (MOR,
DOR, and KOR) in human myocardial tissue. MOR and
DOR immunoreactivity was mainly found in myocardial
cells as well as on sparse individual nerve fibers. KOR
immunoreactivity was found predominantly in myocardial
cells and on ICA cell-like structures. Double immunoflu-
orescence microscopy revealed that DOR colocalized with
the neuronal marker PGP9.5 as well as with the sensory
neuron marker CGRP. CGRP-IR fibers were detectable
either in nerve bundles or as sparse individual nerve fibers
containing varicose-like structures.
In earlier studies, the neuropeptide CGRP was demon-
strated in nerve fibers of the human heart. The CGRP
content in the atria was found to be three- to fourfold
higher than that in the ventricles [31]. Wharton et al. [32]
confirmed these early findings and reported CGRP immu-
noreactivity mainly on scattered individual neurons, gan-
glion neurons, and nerve bundles. Interestingly in the
developing human heart, sensory CGRP-IR innervation
occurs later (18th–24th week of gestation) than the auto-
nomic parasympathetic and sympathetic ones (7th week of
gestation), suggesting a chronological development of the
autonomic and sensory nerves [33, 34]. Peptidergic CGRP-
IR nerve fibers are part of a complex sensory network that
transmits relevant sensory information from the heart to
nearby intrinsic cells as well as to the spinal cord [35].
Consistent with our previous studies in rats [16], we can
now demonstrate that DORs in the human heart are
expressed in CGRP-IR sensory neurons as well as in
Fig. 4 Immunohistochemical localization of kappa opioid receptor
(KOR) (a–e) in human myocardial tissue. a, b KOR was expressed in
sparse solitary nerve processes in cardiac tissue (arrow). d, e KOR
was expressed on long fusiform cells with an eccentrically located
large nucleus (arrow) of the human heart. b–d KOR is expressed in
cardiomyocytes (arrowhead) of the human heart. Bar 20 lm
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myocardial cells, suggesting that opioids regulate both the
transmission of sensory information and the function of
myocardial cells. In addition, we can show the presence of
the other ORs (MOR and KOR) on single nerve fibers and
on myocardial cells, confirming that all three ORs are
expressed in the human heart. Until now, MOR, DOR, and
KOR have been mainly identified by the detection of their
mRNA in cardiomyocytes [18, 19, 36–38]. Moreover,
DOR protein was detected by Western blot and immuno-
histochemistry in ICA cells [37, 38]. The most interesting
previous finding is the demonstration of MOR- and DOR-
specific binding sites in the heart of human volunteers by
the use of MOR- and DOR-specific radioligands and pos-
itron emission tomography [39]. The distribution of these
binding sites was homogeneous throughout the myocar-
dium, with relatively higher uptake in the lateral wall than
in the septum. The specificity of binding was confirmed
with naloxone pretreatment, which decreased radioligand
uptake.
There is a growing body of evidence from experimental
studies of the rodent heart supporting the notion that acti-
vation of the local ORs affects cardiac function. Indeed,
ORs such as DOR in the heart elicit cardioprotective
effects against myocardial infarction and trigger processes
similar to ischemic preconditioning [40, 41]. DOR stimu-
lation also reduces arrhythmias, and preserves the viability
of isolated cells and organs [42, 43]. In addition, DOR
activation enhances the growth of neonatal rat ventricular
myocytes via the extracellular signal-regulated kinase
pathway [44] and mediates antiapoptotic effects in
cardiomyocytes [45]. KOR stimulation is proarrhythmic in
swine [46], but in rats it can exert a pro- or antiarrhythmic
influence [47–50]. In rabbit hearts, KOR agonists inhibit
electric stimulation-induced sympathomimetic effects [51],
whereas in rats MOR activation did not induce precondi-
tioning [52, 53].
It is well established that endogenous ligands for ORs,
i.e., the opioid peptides encephalin and dynorphin and their
Fig. 5 Confocal microscopy of DOR (a, d, g, j) (red fluorescence)
with polyclonal protein gene product 9.5 (PGP9.5) (b, e) or CGRP (h,
k) (green fluorescence) double immunofluorescence in human
myocardial tissue. c, f, i and l are combined images showing
colocalization (double arrows) of DOR with PGP9.5 (c, f) or CGRP
(i, l). Some PGP9.5- or CGRP-immunoreactive nerve fibers (arrow-
heads) do not express DOR. Bar 20 lm (color figure online)
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precursor peptides proenkephalin and prodynorphin, are
expressed in peripheral neuronal terminals of the human
heart [54, 55] and that of other mammalian species,
including the rat (for a review, see [56, 57]). However, the
release of opioid peptides (i.e., OR ligands) from heart
tissue has not been conclusively demonstrated although
preliminary evidence supports this view [58, 59]. Thus, in
the human heart there exists an intrinsic opioid system that
may regulate the parasympathetic and sympathetic control
of the heart as well as myocardial performance. However,
our study has its limitations as tissue samples were taken
within 48 h post mortem, which may contribute to a
potential loss of antigen recognition. Nevertheless, our
results remain in concordance with previous studies
showing the existence of ORs in the human heart by other
techniques [18, 19, 32, 36, 37].
Taken together, our findings demonstrate that ORs in the
human heart are expressed in CGRP-IR sensory nerves, as
well as in myocardial cells and small cells resembling ICA
cells, suggesting a modulatory role of opioids both in the
neural transmission and in the function of myocardial cells.
This study may stimulate further experiments to investigate
systematically the precise subcellular localization of each
OR subtype in the human heart.
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